Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Isreali cancer treatment company seeks investment
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Assistant Manager, International Business Advisory
|Project highlights||NADAV technology - NDV - Mucus virus|
The Israeli cancer treatment company is developing a new biological / drug platform (NADAV technology) - a proprietary strain based on oncolytic virus NDV, which can target a variety of cancers. A series of in vivo, in vitro and clinical studies on NDV strains, show that NDV strains retain the potential selective and targeted cell death (apoptosis) mechanism of human cancer cells. Another virus named Mucus virus can preferentially replicate and kill cancer cells. For the virus to have oncolytic effect, it must be safe for human beings, only kill cancer cells while retaining normal cells, and genetic stability. The company seeks investment.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us